MetaCap

Capricor Therapeutics (CAPR) vs Kamada (KMDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Capricor Therapeutics (CAPR) has outperformed Kamada (KMDA) over the past year, gaining 32.0% versus a gain of 14.7%. Over five years, CAPR leads with a +122.6% price change compared with +22.7% for KMDA. Kamada is the larger company by market cap ($446.8 million vs $441.3 million), about 1.0 times the size.

Kamada pays a dividend yielding 7.24%, while Capricor Therapeutics does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAPR+32.00%KMDA+14.67%
+542%+241%-60%
Nov 21, 20251 yearNov 20, 2026
CAPR+127.93%KMDA+38.21%
+1009%+464%-80%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAPR versus KMDA key metrics
MetricCAPRKMDA
Share price$7.59$7.74
Market cap$441.30M$446.85M
1-day change+0.80%-1.15%
YTD return-73.70%+9.63%
1-year return+32.00%+14.67%
5-year return+122.58%+22.66%
P/E ratio (TTM)—20.37
Forward P/E—13.34
EPS (TTM)$-2.65$0.38
Dividend yield0.00%7.24%
Annual dividend$0.00$0.56
Revenue (latest FY)$0$180.46M
Revenue growth (YoY)-100.00%+12.12%
Net income (latest FY)$-105.04M$20.20M
Gross margin—42.34%
Operating margin—14.54%
Net margin—11.19%
52-week high$40.37$9.35
52-week low$2.96$6.63
Distance from 52-week high-81.20%-17.22%
Analyst consensusbuystrong_buy
Avg. price target upside+259.03%+77.65%
Average volume4.73M121.87K
Shares outstanding58.14M57.73M
Employees231462
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAPR has outperformed KMDA by 17.3 percentage points over the past year.
  • Kamada offers a meaningfully higher dividend yield (7.24% vs 0.00%).
  • Kamada grew revenue faster in its latest fiscal year (+12.12% vs -100.00%).

About Capricor Therapeutics

CAPR stock →

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.

Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees

About Kamada

KMDA stock →

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees

CAPR vs KMDA FAQ

Which is bigger, Capricor Therapeutics or Kamada?

Kamada (KMDA) is larger, with a market capitalization of $446.85M compared with $441.30M for Capricor Therapeutics (CAPR).

Which stock has performed better over the past year, CAPR or KMDA?

CAPR returned +32.00% over the past 12 months, compared with +14.67% for KMDA (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Capricor Therapeutics or Kamada?

Kamada pays a dividend yielding 7.24%, while Capricor Therapeutics does not currently pay a regular dividend.

Are Capricor Therapeutics and Kamada in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons